SAN DIEGO, April 12, 2010 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly
Update Conference Call for the first quarter of 2010 on
Monday, April 19, 2010 at
8:30 a.m. ET/5:30 a.m. PT. Daniel M.
Bradbury, Amylin's president and chief executive officer,
will lead the call. On the same date pre-market, Amylin will
release financial results for the first quarter of 2010.
The call will be webcast live through the "Investors" section of
Amylin's corporate Web site and a recording will be made available
following the close of the call. To access the webcast, please log
on to www.amylin.com approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. For those without access to the Internet, the live call
may be accessed by phone by calling (800) 884-5695
(U.S./Canada) or (617) 786-2960
(international), participant passcode# 11172097. A replay of the
call will also be available by phone beginning approximately two
hours after the close of the call and can be accessed at (888)
286-8010 (U.S./Canada) or (617)
801-6888 (international), passcode# 57594716.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and
BYETTA® (exenatide) injection. Amylin's research and
development activities leverage the Company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is headquartered in San
Diego, California. Further information on Amylin
Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.